These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 1360665

  • 1. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK, Katzenstein D, Moses LE, Merigan TC.
    Proc Natl Acad Sci U S A; 1992 Dec 01; 89(23):11204-8. PubMed ID: 1360665
    [Abstract] [Full Text] [Related]

  • 2. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA, Schwartz DH, Fabry JA, Lieberman J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep 01; 10(1):27-35. PubMed ID: 7648281
    [Abstract] [Full Text] [Related]

  • 3. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
    Stanhope PE, Liu AY, Pavlat W, Pitha PM, Clements ML, Siliciano RF.
    J Immunol; 1993 May 15; 150(10):4672-86. PubMed ID: 8097759
    [Abstract] [Full Text] [Related]

  • 4. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.
    Stanhope PE, Clements ML, Siliciano RF.
    J Infect Dis; 1993 Jul 15; 168(1):92-100. PubMed ID: 8099941
    [Abstract] [Full Text] [Related]

  • 5. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD.
    J Virol; 1994 May 15; 68(5):3145-53. PubMed ID: 7908700
    [Abstract] [Full Text] [Related]

  • 6. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, Siliciano RF.
    J Exp Med; 1992 Dec 01; 176(6):1531-42. PubMed ID: 1460417
    [Abstract] [Full Text] [Related]

  • 7. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW.
    AIDS Res Hum Retroviruses; 1998 Jul 20; 14(11):925-37. PubMed ID: 9686639
    [Abstract] [Full Text] [Related]

  • 8. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C, Golding B, Inman J, Blackburn R, Manischewitz J, Highet P, Golding H.
    J Virol; 1996 May 20; 70(5):3084-92. PubMed ID: 8627787
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
    Achour A, Moukrim Z, Picard O, Bizzini B, Burny A, Zagury D.
    Cell Mol Biol (Noisy-le-grand); 1995 May 20; 41(3):395-400. PubMed ID: 7580833
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance.
    Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA.
    Proc Natl Acad Sci U S A; 1993 Feb 01; 90(3):948-52. PubMed ID: 8094248
    [Abstract] [Full Text] [Related]

  • 13. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
    Kundu SK, Merigan TC.
    AIDS; 1992 Jul 01; 6(7):643-9. PubMed ID: 1354446
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines.
    el-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ.
    J Infect Dis; 1993 Aug 01; 168(2):306-13. PubMed ID: 8335968
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB.
    J Virol; 1994 Sep 01; 68(9):6103-10. PubMed ID: 8057491
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA.
    Ann N Y Acad Sci; 1995 Nov 27; 772():198-208. PubMed ID: 8546393
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.